PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 20578904-0 2010 Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy. Atorvastatin 115-127 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 19-24 21083855-1 2011 OBJECTIVES: Atorvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in cholesterol synthesis, lowers plasma cholesterol and triglyceride (TG) levels dose dependently. Atorvastatin 12-24 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 42-89 21123766-2 2011 This study examined how HMG-CoAR inhibition by atorvastatin modulates expression of key genes involved in intestinal cholesterol metabolism. Atorvastatin 47-59 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 24-32 21123766-6 2011 Atorvastatin significantly increased intestinal mRNA levels of HMG-CoAR (59%), LDL receptor (LDLR) (52%), PCSK9 (187%), SREBP-2 (44%), and HNF-4alpha (13%). Atorvastatin 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 63-71 21123766-9 2011 These results indicate that HMG-CoAR inhibition with atorvastatin stimulates the intestinal expression of NPC1L1, LDLR, and PCSK9; increases cholesterol absorption; and reduces expression of ABCG5/8; these effects are most likely mediated by upregulation of the transcription factors SREBP-2 and HNF-4alpha. Atorvastatin 53-65 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 28-36 20714791-2 2010 Atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, exerts anti-inflammatory effects in the cardiovascular system beyond its cholesterol-lowering property. Atorvastatin 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 16-73 20953062-9 2010 CONCLUSIONS: In patients with mild to moderate hypertension, atorvastatin reduces postganglionic MSNA, which supports the hypothesis that HMG-CoA reductase plays a role in sympathetic nervous system activity. Atorvastatin 61-73 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 138-155 20177788-9 2010 Twenty-two patients were started on 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (atorvastatin or simvastatin). Atorvastatin 106-118 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 36-93 20578904-3 2010 We studied the association between 18 single-nucleotide polymorphisms (SNPs) in six genes (HMGCR, CETP, APOAI, ABCB1, CYP3A4, CYP7A1) in response to atorvastatin therapy (20 mg/day) in 265 newly diagnosed CAD patients using multivariable adjusted general linear regression. Atorvastatin 149-161 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 91-96 20678686-1 2010 BACKGROUND: Atorvastatin calcium is a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor indicated for the prevention of cardiovascular disease and for the treatment of dyslipidemia. Atorvastatin 12-32 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 38-85 20653359-10 2010 Evidence demonstrates that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) therapy (i.e., atorvastatin and rosuvastatin) significantly reduces surrogate cardiovascular markers, particularly LDL, in patients with ESRD requiring hemodialysis; however, no statin has proved to reduce cardiovascular morbidity or mortality in this population. Atorvastatin 109-121 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 27-74 20108992-1 2010 Amlodipine/atorvastatin (Caduet) is a single-tablet, fixed-dose combination of the dihydropyridine calcium channel antagonist amlodipine and the HMG-CoA reductase inhibitor atorvastatin. Atorvastatin 11-23 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 145-162 19930424-5 2010 In the present study, we examined the effect of atorvastatin on the expression of HMGCR, LDLR and LDLR-related protein (LRP) mRNA in circulating mononuclear cells. Atorvastatin 48-60 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 82-87 20387911-2 2010 BACKGROUND: A previous study in 4703 patients suggested that a single-pill combination of amlodipine and atorvastatin is associated with greater adherence to therapy than a two-pill calcium channel antagonist (calcium channel blocker [CCB]) and HMG-CoA reductase inhibitor (statin) regimen. Atorvastatin 105-117 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 245-262 20712135-6 2010 Importantly, atorvastatin (CAS 134523-03-8), an HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase inhibitor, strongly suppressed their effects on aldosterone production. Atorvastatin 13-25 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 57-105 20108992-1 2010 Amlodipine/atorvastatin (Caduet) is a single-tablet, fixed-dose combination of the dihydropyridine calcium channel antagonist amlodipine and the HMG-CoA reductase inhibitor atorvastatin. Atorvastatin 173-185 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 145-162 19237515-10 2009 Finally, we demonstrated expression of HMG-CoA reductase, the primary target of atorvastatin, in platelet cytosol. Atorvastatin 80-92 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 39-56 18395165-3 2008 Atorvastatin is a hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor demonstrated to be effective in reducing both cholesterol (CHOL) and triglyceride (TG) levels in humans. Atorvastatin 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 18-70 19067673-3 2009 The aim of this study was to assess the association in the low-density lipoprotein cholesterol reduction by atorvastatin and (TTA)n polymorphism in the 3-hydroxy-3-methylglutaryl-coenzyme A reductase gene in patients with coronary artery disease. Atorvastatin 108-120 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 152-199 19067673-11 2009 In conclusion, the changes induced by atorvastatin treatment on low-density lipoprotein cholesterol, total cholesterol, triglycerides, high-sensitivity C-reactive protein and free F(2)-isoprostane concentrations were not related to the presence of 3-hydroxy-3-methylglutaryl-coenzyme A reductase polymorphism (TTA)n. Atorvastatin 38-50 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 248-295 18720283-1 2008 Atorvastatin is a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor that is mainly metabolized by cytochrome P450 (CYP) 3A4. Atorvastatin 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 18-75 20069794-1 2009 The objective of the study was to increase the solubility, stability, and dissolution rate of atorvastatin calcium (ATN Ca), a poorly water-soluble 3-hydroxy 3-methyl glutaryl CoA (HMG-CoA) reductase inhibitor through inclusion complexation with beta-cyclodextrin (beta-CD). Atorvastatin 94-114 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 148-199 18261731-0 2008 The creatine kinase response to eccentric exercise with atorvastatin 10 mg or 80 mg. INTRODUCTION: Hydroxy-methyl-glutaryl co-enzyme A (HMG-CoA) reductase inhibitors or statins are well tolerated by most patients, but can produce a variety of skeletal muscle problems including myalgia, creatine kinase (CK) elevations and clinically important rhabdomyolysis. Atorvastatin 56-68 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 99-154 18547436-8 2008 Atorvastatin administration (HMGCoA reductase inhibitor) significantly increased plasma PCSK9 (7.40%, p = 0.033) and these changes were inversely correlated with changes in LDLC levels (r = -0.393, p = 0.012). Atorvastatin 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 29-45 18303938-1 2008 Amlodipine/atorvastatin (Caduet) is a once-daily fixed-dose combination of the dihydropyridine calcium channel antagonist amlodipine and the HMG-CoA reductase inhibitor atorvastatin. Atorvastatin 11-23 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 141-158 18303938-1 2008 Amlodipine/atorvastatin (Caduet) is a once-daily fixed-dose combination of the dihydropyridine calcium channel antagonist amlodipine and the HMG-CoA reductase inhibitor atorvastatin. Atorvastatin 169-181 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 141-158 17622571-0 2007 Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis. Atorvastatin 34-46 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 14-30 17651990-1 2008 INTRODUCTION: A Tecan-based enzyme inhibition assay has been developed for the determination of atorvastatin-derived "active" and "total" (active inhibitors plus atorvastatin lactone and other potential inhibitors following base hydrolysis) 3-hydroxy-3-methylglutaryl-Coenzyme A (HMG-CoA) reductase inhibitor concentrations in human plasma. Atorvastatin 96-108 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 241-298 17622571-8 2007 Atorvastatin"s effects on MYC were specific to the inhibition of HMGcoA reductase, as treatment with mevalonate, the product of HMG-CoA reductase activity, abrogated these effects and inhibited the ability of atorvastatin to reverse or suppress tumorigenesis. Atorvastatin 209-221 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 65-81 17622571-10 2007 Thus, atorvastatin, by inhibiting HMGcoA reductase, induces changes in phosphoprotein signaling that in turn prevent MYC-induced lymphomagenesis. Atorvastatin 6-18 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 34-50 17622571-8 2007 Atorvastatin"s effects on MYC were specific to the inhibition of HMGcoA reductase, as treatment with mevalonate, the product of HMG-CoA reductase activity, abrogated these effects and inhibited the ability of atorvastatin to reverse or suppress tumorigenesis. Atorvastatin 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 65-81 16503719-9 2006 CONCLUSION: By inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase, atorvastatin lowered concentrations of several inflammatory molecules derived from basal-state endothelial cells in a concentration-dependent manner. Atorvastatin 75-87 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 26-73 19804188-2 2006 Atorvastatin is a 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitor that is taken once daily. Atorvastatin 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 18-65 17529847-1 2007 OBJECTIVE: To test whether the 3-hydroxy-3-methylglutaryl- coenzyme A reductase inhibitor atorvastatin can slow down the progression of presbycusis. Atorvastatin 90-102 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 31-79 17261740-3 2007 Additionally, a new class of drugs, HMG CoA-reductase inhibitors (statins), specifically high-dose atorvastatin, has been shown to be safe and effective for secondary stroke prevention. Atorvastatin 99-111 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 36-53 16554298-5 2006 280, 26263-26277), we investigated whether IL-18 induces SMC migration in an MMP-dependent manner and whether the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin can inhibit this response. Atorvastatin 165-177 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 114-154 16356805-4 2005 Standard treatment (statin) with a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (pravastatin 40 mg/day) resulted in a 22% reduction in LDL cholesterol levels at 30 days compared with a 51% reduction with intensive therapy (atorvastatin 80 mg/day). Atorvastatin 246-258 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 35-92 16356809-5 2005 Certain agents, including the antihypertensive drug amlodipine and the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) atorvastatin, are known to influence endothelial function and NO bioavailability directly; these properties may contribute to clinical benefits. Atorvastatin 138-150 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 71-118 16185099-6 2005 In CARDS (Collaborative Atorvastatin Diabetes Study), the first large HMG-CoA reductase inhibitor study to enroll only patients with type 2 diabetes, atorvastatin reduced cardiovascular events by 37% (p=0.001) compared with placebo. Atorvastatin 150-162 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 70-87 16284747-1 2005 AIMS/HYPOTHESIS: The aim of this study was to determine the pattern of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor atorvastatin on cardiovascular events in patients with type 2 diabetes and no prior history of cardiovascular disease (CVD). Atorvastatin 147-159 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 89-136 15962651-1 2005 OBJECTIVE: The aim of this study was to determine whether HMGCoA reductase inhibitor with atorvastatin can modulate endothelial function in type II diabetics having average cholesterol and no prior cardiovascular disease. Atorvastatin 90-102 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 58-74 16327254-2 2005 HMG-CoA reductase inhibitor drugs or statins (simvastatin, atorvastatin, pravastatin) reduce the relative risk of IS by between 18 and 51% in patients with IHD, in patients with high vascular disease risk and in hypertensive patients with other RFs, acute coronary syndrome, and type 2 diabetes mellitus. Atorvastatin 59-71 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-17 16020911-4 2005 In both cell lines, the statins (atorvastatin, cerivastatin and pitavastatin) induced the expression of four genes, which relate to cholesterol metabolism, namely, HMG-CoA synthase 1, HMG-CoA reductase, farnesyl diphosphate synthase and isopentenyl-diphosphate delta isomerase. Atorvastatin 33-45 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 184-201 16360444-1 2005 OBJECTIVES: To evaluate a commonly used 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor-atorvastatin-for potential activity against human bladder cancer. Atorvastatin 108-120 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 40-97 12816876-5 2003 Three- to 4-fold increases in MCP-1 and IL-8 release were observed at endotoxin concentrations of 100 pg/mL; these increases were inhibited by the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor atorvastatin. Atorvastatin 205-217 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 147-194 15488897-7 2004 HMG-CoA reductase inhibitor, atorvastatin increased GTPCH1 mRNA and activity, and BH4 level. Atorvastatin 29-41 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-17 15381079-7 2004 The endothelial death and beta4 integrin upregulation by ATV could be reversed by intermediate metabilites of the HMG-CoA reductase pathway mevalonate or GGPP, but not by FPP, suggesting that these effects were results of specific inhibition of the pathway. Atorvastatin 57-60 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 114-131 14687410-0 2003 Atorvastatin, 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, reduces bone resorption in the elderly. Atorvastatin 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 14-61 14564679-1 2003 We aimed to examine postprandial dyslipidemia in normolipidemic patients with coronary artery disease (CAD) and the effects of treatment with an hydroxymethyl glutaryl coenzyme A (HMG-CoA) reductase inhibitor (atorvastatin). Atorvastatin 210-222 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 145-198 14578459-6 2003 We investigated the effect that Atorvastatin, a 3-hydroxy 3-methylglutaryl CoA (HMG-CoA) reductase inhibitor that prevents Rho geranylgeranylation, had on subcellular localization and activity of Rho proteins as well as the metastatic ability of melanoma cells. Atorvastatin 32-44 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 48-98 14684313-1 2004 An efficient synthesis of N3,4-diphenyl-5-(4-fluorophenyl)-2-isopropyl-1H-3-pyrrolecarboxamide, a key intermediate for the synthesis of an effective HMG-CoA reductase inhibitor atorvastatin, is described. Atorvastatin 177-189 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 149-166 12648031-1 2003 INTRODUCTION: The objective of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS) was to compare the efficacy and safety of the five 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors in a randomised, controlled, yet large-scale study. Atorvastatin 35-47 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 158-215 12960612-3 2003 We show here that two different 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins), atorvastatin and simvastatin, strongly increase the expression and functional activity of TM in human umbilical vein endothelial cells, human coronary artery endothelial cells, and EA.hy926 endothelial cells. Atorvastatin 102-114 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 32-79 12612979-4 2003 METHODS: In a prospective, controlled open-label study, the authors have evaluated the effects of one-year treatment with atorvastatin, a 3-hydroxy-3-methyglutaryl coenzyme A (HMG-CoA) reductase inhibitor, versus no treatment on proteinuria and progression of kidney disease in 56 patients with chronic kidney disease. Atorvastatin 122-134 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 138-194 12612140-10 2003 In addition, dealcoholized and alcoholized red wine and atorvastatin significantly increased 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase mRNA and LDL receptor binding activity relative to controls. Atorvastatin 56-68 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 93-150 12433810-4 2002 Although treatment with the active (+), but not the inactive (-), enantiomer of atorvastatin increased the amount of HMG-CoA reductase mRNA, treatment with each enantiomer significantly induced both CYP2B6 and CYP3A mRNA levels. Atorvastatin 80-92 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 117-134 12426205-0 2002 3-hydroxy-3-methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells. Atorvastatin 93-105 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-47 12181212-2 2002 AIM: To evaluate the efficacy and safety of monotherapy with atorvastatin, an HMG-CoA reductase inhibitor with superior efficacy in lowering low density lipoprotein cholesterol and triglyceride concentrations, in patients with dysbetalipoproteinaemia and severe combined dyslipidaemia. Atorvastatin 61-73 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 78-95 12145183-0 2002 Glucose increases endothelial-dependent superoxide formation in coronary arteries by NAD(P)H oxidase activation: attenuation by the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor atorvastatin. Atorvastatin 190-202 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 132-179 12494218-1 2002 AIM: To study the influence of treatment with HMG-CoA reductase inhibitor atorvastatin on endothelial function in patients with familial hypercholesterolemia type IIa. Atorvastatin 74-86 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 46-63 12017409-2 2002 OBJECTIVE: The goal of this study was to develop a preliminary pharmacodynamic model for dosing of the hydroxymethylglutaryl coenzyme A (HMG-CoA)-reductase inhibitors simvastatin and atorvastatin using neural network analysis. Atorvastatin 183-195 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 103-155 11918754-2 2002 This double-blind randomized study investigated the efficacy and safety of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, atorvastatin, in continuous ambulatory peritoneal dialysis (CAPD) patients with dyslipidemia. Atorvastatin 148-160 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 79-136 12769127-2 2002 Rosuvastatin, like atorvastatin, has a plasma half-life of about 20 h and is a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. Atorvastatin 19-31 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 99-156 11887170-3 2002 We investigated the potential hypolipidemic effects of atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor with good triglyceride lowering properties, in patients with combined dyslipidemia and evidence of impaired fasting glucose or type 2 diabetes. Atorvastatin 55-67 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 71-128 11772327-2 2002 Rosuvastatin, like atorvastatin, has a plasma half-life of about 20 h and is a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. Atorvastatin 19-31 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 99-156 11831546-1 2002 The authors assessed the mutual influence of the immunosuppressant everolimus (Certican) and the HMG-CoA reductase inhibitors atorvastatin and pravastatin when coadministered based on pharmacokinetic and pharmacodynamic measures. Atorvastatin 126-138 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 97-114 11038166-0 2000 Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Atorvastatin 118-130 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 67-107 11336625-1 2001 Atorvastatin (Lipitor, Pfizer) is a safe and effective 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitor (statin). Atorvastatin 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 55-106 11336625-1 2001 Atorvastatin (Lipitor, Pfizer) is a safe and effective 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitor (statin). Atorvastatin 14-21 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 55-106 14728043-6 2001 Combination therapy with colesevelam plus hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (lovastatin, simvastatin or atorvastatin) was associated with additive reductions in serum levels of LDL-cholesterol and total cholesterol, relative to either agent alone. Atorvastatin 134-146 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 42-94 11693468-1 2001 UNLABELLED: Atorvastatin is a synthetic hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. Atorvastatin 12-24 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 40-92 11474489-1 2001 Atorvastatin is a potent hydroxy-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitor that decreases low-density lipoprotein (LDL) cholesterol and triglyceride concentrations, but little is known about its effects on LDL subtype distribution in different types of hyperlipoproteinemia. Atorvastatin 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 25-79 11074211-1 2000 The purpose of this study was to determine if long-term use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (atorvastatin, fluvastatin, lovastatin, pravastatin, or simvastatin) resulted in tachyphylaxis (a decreasing response to a physiologically active agent). Atorvastatin 123-135 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 63-110 11038166-1 2000 In an in vitro study, we compared the cytochrome P450 (CYP)-dependent metabolism and drug interactions of the acid and lactone forms of the 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitor atorvastatin. Atorvastatin 197-209 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 140-186 10690940-1 2000 Atorvastatin is a new hepatic hydroxymethyl glutaryl coenzyme A (HMG-CoA) reductase inhibitor that has been demonstrated to be efficacious in reducing both triglyceride (TG) and cholesterol (CHOL) levels in humans. Atorvastatin 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 30-83 10907971-7 2000 Atorvastatin was the most cost-effective HMG-CoA reductase inhibitor. Atorvastatin 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 41-58 10856769-7 2000 This effect has been demonstrated for the HMG-CoA reductase inhibitor atorvastatin which, in addition to its ability to markedly decrease the total LDL circulating mass, can also shift the LDL profile towards less dense, larger species. Atorvastatin 70-82 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 42-59 10634817-3 2000 In the present study, we evaluated the impact of atorvastatin, a newly developed inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase, on the cholesteryl ester transfer protein (CETP)-mediated remodeling of apolipoprotein (apo) B-containing lipoprotein subspecies, and more specifically, the particle subpopulations of VLDL and LDL in CHL. Atorvastatin 49-61 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 94-150 9549635-1 1997 The objective of this study was to determine the effects of renal dysfunction on the steady-state pharmacokinetics and pharmacodynamics of atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Atorvastatin 139-151 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 155-202 10500210-4 1999 Inhibition of the cholesterol metabolic pathway by the hydrophobic 3-hydroxy-3-methylglutaryl CoA (HMGCoA) reductase inhibitors, simvastatin and atorvastatin, reversed the effect of lipoprotein-depleted serum and up-regulated TGFbetaRII expression, whereas the hydrophilic HMGCoA reductase inhibitor, pravastatin, had no effect. Atorvastatin 145-157 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 273-289 9856919-10 1998 The cost-effectiveness of HMG-CoA reductase inhibition in primary and secondary prevention of coronary heart disease has been improved with the introduction of atorvastatin. Atorvastatin 160-172 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 26-43 9551707-1 1998 OBJECTIVE: To determine the effects of cimetidine on the steady-state pharmacokinetics and pharmacodynamics of atorvastatin, a 3-hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitor. Atorvastatin 111-123 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 127-182 9793596-8 1998 DATA SYNTHESIS: Atorvastatin is a recent hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor for the treatment of primary hypercholesterolemia, mixed dyslipidemias, and homozygous familial hypercholesterolemia. Atorvastatin 16-28 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 41-93 9821014-3 1998 Atorvastatin, a recently introduced statin, produces pronounced lipid-lowering via inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. Atorvastatin 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 97-154 9485553-1 1998 An HMG-CoA reductase inhibition assay was developed and validated for quantitation of atorvastatin in human, dog, rat, and mouse plasma. Atorvastatin 86-98 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 3-20 9512650-0 1998 Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase: a comparison of atorvastatin and simvastatin. Atorvastatin 93-105 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 35-75 9399600-0 1997 Atorvastatin calcium: an addition to HMG-CoA reductase inhibitors. Atorvastatin 0-20 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 37-54 10684465-1 1997 BACKGROUND: Atorvastatin calcium (Lipitor) is a new 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor. Atorvastatin 12-32 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 52-109 10684465-1 1997 BACKGROUND: Atorvastatin calcium (Lipitor) is a new 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor. Atorvastatin 34-41 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 52-109 9374129-2 1997 The efficacy and mechanism of action of a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, atorvastatin, was therefore investigated in seven homozygotes undergoing apheresis. Atorvastatin 105-117 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 46-93 9180240-1 1997 Preclinical and clinical data on atorvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, indicate that it has superior activity in treating a variety of dyslipidemic disorders characterized by elevations in low-density lipoprotein cholesterol (LDL-C) and/or triglycerides. Atorvastatin 33-45 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 53-110 8988072-1 1996 This study examined the pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an investigational inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, in 50 healthy subjects by means of a randomized, double-blind parallel-group design. Atorvastatin 74-86 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 120-177 10225774-5 1997 Better control of hypercholesterolemia results from combining apheresis with a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, atorvastatin. Atorvastatin 142-154 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 83-130 33027917-3 2020 This study aimed to find out the effects of major genetic variants in 3-Hydroxy-3-Methylglutaryl-CoA Reductase (HMGCR), Apolipoprotein E (APOE), and Solute Carrier Organic Anion (SLCO1B1) genes on atorvastatin response among DM2 patients. Atorvastatin 197-209 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 70-110 8877677-0 1996 Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects. Atorvastatin 46-58 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 82-99 8877677-1 1996 Tolerance and pharmacokinetics after single-dose administration of atorvastatin, an investigational inhibitor of HMG-CoA reductase, were examined in 22 healthy volunteers in a three-period, partially-blinded study. Atorvastatin 67-79 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 113-130 8690818-1 1996 Atorvastatin is a new 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor that reduces plasma cholesterol by inhibiting cholesterol synthesis and increasing cellular uptake of low density lipoproteins. Atorvastatin 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 22-79 7749881-2 1995 Atorvastatin is a new 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor under development. Atorvastatin 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 22-79 34140545-0 2021 Concomitant attenuation of HMGCR expression and activity enhances the growth inhibitory effect of atorvastatin on TGF-beta-treated epithelial cancer cells. Atorvastatin 98-110 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 27-32 34140545-7 2021 Moreover, treatment of cells with atorvastatin prior to TGF-beta treatment enhanced this effect, which was further potentiated by the simultaneous reduction in the expression of the statin target enzyme, 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR). Atorvastatin 34-46 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 204-251 34140545-7 2021 Moreover, treatment of cells with atorvastatin prior to TGF-beta treatment enhanced this effect, which was further potentiated by the simultaneous reduction in the expression of the statin target enzyme, 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR). Atorvastatin 34-46 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 253-258 31450089-1 2019 Atorvastatin (ATV) and its two active metabolites, o-hydroxy atorvastatin acid (o-OH-ATV) and p-hydroxy atorvastatin acid (p-OH-ATV) are responsible for its HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme-A) reductase inhibitory activity, while its corresponding inactive lactone forms (LAC) are related to the manifestation of myopathy. Atorvastatin 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 166-214 31423616-1 2019 Atorvastatin (ATO) is a 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor widely used to treat hypercholesterolemia. Atorvastatin 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 24-64 31423616-1 2019 Atorvastatin (ATO) is a 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor widely used to treat hypercholesterolemia. Atorvastatin 14-17 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 24-64 32523820-3 2020 We describe a case of anti-HMGCR myopathy in a 59-year-old male with a prior history of statin intolerance presenting with markedly elevated creatinine kinase, myoglobinuria, and one month of progressive proximal muscle weakness after restarting atorvastatin 10 months prior to admission. Atorvastatin 246-258 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 27-32 31450089-1 2019 Atorvastatin (ATV) and its two active metabolites, o-hydroxy atorvastatin acid (o-OH-ATV) and p-hydroxy atorvastatin acid (p-OH-ATV) are responsible for its HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme-A) reductase inhibitory activity, while its corresponding inactive lactone forms (LAC) are related to the manifestation of myopathy. Atorvastatin 14-17 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 166-214 31253872-6 2019 Neratinib interacted with the PKG activator sildenafil and the HMG CoA reductase inhibitor atorvastatin to further reduce K-RAS expression, and to further enhance cell killing. Atorvastatin 91-103 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 63-80 31005367-4 2019 Moreover, both conjugates were able to release atorvastatin, and consequently showed dramatic inhibition of beta-hydroxy-beta-methylglutaryl-CoA (HMG-CoA) reductase and increased LDL receptors on cell surface. Atorvastatin 47-59 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 108-164 28802579-1 2018 OBJECTIVE: The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor atorvastatin has been reported to exert vasculo-protective action in diabetes. Atorvastatin 73-85 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 15-62 30034619-3 2018 Here, we show that attenuation of HMGCR expression in the presence of atorvastatin leads to stronger growth inhibition than dual target blockade of the mevalonate pathway in relatively statin resistant cell lines, mainly through inhibition of protein prenylation pathways. Atorvastatin 70-82 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 34-39 30034619-4 2018 Thus, combined inhibition of the mevalonate pathway"s rate-limiting enzyme, HMGCR, can improve atorvastatin"s growth inhibitory effect on epithelial- and mixed mesenchymal-epithelial cancer cells, a finding that may have implications for the design of future anti-metastatic cancer therapies. Atorvastatin 95-107 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 76-81 29615666-5 2018 Notably, significant upregulation of genes involved in unsaturated fatty acid metabolism [stearoyl-CoA desaturase (SCD)] and cholesterol biosynthesis [3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR)], were associated with atorvastatin insensitivity. Atorvastatin 223-235 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 151-191 30595323-0 2018 Randomized controlled trial comparing the efficacy of daily and every other day atorvastatin therapy and its correlation with serum hydroxymethylglutaryl-CoA reductase enzyme levels in naive dyslipidemic patients. Atorvastatin 80-92 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 132-167 29427701-10 2018 Network analysis indicated that atorvastatin-modulated miRNAs regulate key cholesterol genes (ABCA1, HMGCR, INSIG1, LDLR, LPL, SCAP and SREBF1). Atorvastatin 32-44 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 101-106 27738832-1 2017 BACKGROUND: Atorvastatin is a 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitor widely used in treatment of hypercholesterolemia and prevention of coronary heart disease and has various pleiotropic effects. Atorvastatin 12-24 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 30-87 29065216-6 2017 Total cholesterol concentration decreased after GINST treatment for 24 and 48 h. Expression of HMGCR decreased more with GINST than with the inhibitors, U18666A and atorvastatin, after 48 h in a dose-dependent manner. Atorvastatin 165-177 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 95-100 28745862-4 2017 Moreover, both G-AT and G-K-AT were able to release atorvastatin and consequently achieve significant inhibition against 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase. Atorvastatin 52-64 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 121-179 29441875-1 2017 Atorvastatin, as 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, is a widely prescribed medication for the treatment of dyslipidemia. Atorvastatin 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 17-74 26886305-4 2016 For testing, we selected atorvastatin calcium (ATC), an antilipid BCS class II drug that inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase and is marketed in crystalline and amorphous forms. Atorvastatin 25-45 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 98-145 26408409-0 2016 HMGCR rs17671591 SNP Determines Lower Plasma LDL-C after Atorvastatin Therapy in Chilean Individuals. Atorvastatin 57-69 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-5 26408409-4 2016 Hence, we aimed to evaluate the contribution of PCSK9 rs7552841 and HMGCR rs17671591 SNPs as genetic determinants of atorvastatin response in Chilean hypercholesterolaemic individuals. Atorvastatin 117-129 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 68-73 26408409-12 2016 Our data suggest that the HMGCR rs17671591 polymorphism can constitute a genetic marker of lower plasma LDL-C and enhanced HDL-C concentration after atorvastatin therapy in the Chilean population. Atorvastatin 149-161 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 26-31 26886305-4 2016 For testing, we selected atorvastatin calcium (ATC), an antilipid BCS class II drug that inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase and is marketed in crystalline and amorphous forms. Atorvastatin 47-50 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 98-145 26091578-5 2015 Due to similar expression levels of the drug target HMG-CoA reductase in both cell types, cellular accumulation of atorvastatin was assessed, revealing enhanced uptake in HCASMC most likely driven by significant expression of OATP2B1, a known uptake transporter for atorvastatin. Atorvastatin 115-127 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 52-69 26908399-4 2016 In vitro, activator protein 1 activity was inhibited by two 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, rosuvastatin and atorvastatin, in stretch-stimulated human venous smooth muscle cells. Atorvastatin 137-149 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 60-107 25745361-3 2015 Here we show that atorvastatin (Lipitor), an inhibitor of hydroxymethylglutaryl co-enzyme A (HMG-CoA) reductase that is a rate-limiting enzyme of mevalonate pathway, down-regulates expression of PBK by impairing protein geranylgeranylation. Atorvastatin 18-30 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 58-111 25668447-5 2015 Many lipid-related protein abundances were increased in HepG2 cells treated by atorvastatin, including HMGCR, FDFT, SQLE, and LDLR, while the abundances of proteins involved in cellular response to stress and apoptosis were decreased. Atorvastatin 79-91 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 103-108 25745361-3 2015 Here we show that atorvastatin (Lipitor), an inhibitor of hydroxymethylglutaryl co-enzyme A (HMG-CoA) reductase that is a rate-limiting enzyme of mevalonate pathway, down-regulates expression of PBK by impairing protein geranylgeranylation. Atorvastatin 32-39 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 58-111 25591572-5 2015 RESULTS: Atorvastatin is a reversible and competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, decreasing the de novo cholesterol synthesis. Atorvastatin 9-21 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 67-114 25311809-5 2014 Inhibition of 3-hydroxy-3-methylglutaryl CoA reductase, the rate-limiting enzyme of the mevalonate pathway, by lipophilic statins such as simvastatin and atorvastatin resulted in a specific inhibition of B cell activation via CD40 and impaired their ability to act as stimulatory APCs for allospecific T cells. Atorvastatin 154-166 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 14-54 25022881-0 2014 Molecular modeling studies of atorvastatin analogues as HMGR inhibitors using 3D-QSAR, molecular docking and molecular dynamics simulations. Atorvastatin 30-42 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 56-60 24895437-5 2014 Atorvastatin reduced HMGCoA-R enzymatic activity and intracellular cholesterol synthesis in vitro; however, inflammatory stress weakened these suppressive effects. Atorvastatin 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 21-29 24895437-6 2014 Atorvastatin at concentrations of 15 microM inhibited HMGCoA-R activity by 50% (IC50) in HMCs, but the same concentration in the presence of interleukin (IL)-1beta resulted in only 30% inhibition of HMGCoA-R activity in HMCs. Atorvastatin 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 54-62 24895437-6 2014 Atorvastatin at concentrations of 15 microM inhibited HMGCoA-R activity by 50% (IC50) in HMCs, but the same concentration in the presence of interleukin (IL)-1beta resulted in only 30% inhibition of HMGCoA-R activity in HMCs. Atorvastatin 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 199-207 25013913-2 2014 Previously we could induce T cell tolerance by applying a 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitor (HMGCRI) atorvastatin, which also modulates MHC class II expression and has therapeutic potential in autoimmune disease. Atorvastatin 128-140 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 58-108 24575888-0 2014 Asymmetric synthesis of the HMG-CoA reductase inhibitor atorvastatin calcium: an organocatalytic anhydride desymmetrization and cyanide-free side chain elongation approach. Atorvastatin 56-76 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 28-45 24932497-7 2014 Adhesion was also inhibited by CASMC pre-treatment with the HMG-CoA-reductase inhibitor atorvastatin and the PPARgamma agonist rosiglitazone, which suggests a further mechanism for the anti-inflammatory action of these drugs. Atorvastatin 88-100 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 60-77 22569288-1 2012 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitory activity of atorvastatin lasts upto 20-30 hours. Atorvastatin 71-83 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-47 24783072-2 2014 Of these, Atorvastatin, because of its prolonged 3-hydroxy-3-methylglutaryl-coenzyme A (HMG CoA) reductase inhibition has been considered for alternate day therapy in primary prevention of (CHD). Atorvastatin 10-22 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 49-106 24232833-1 2014 Ethyl (R)-4-cyano-3-hydroxybutanoate (HN) is an important chiral synthon for side chain of the cholesterol-lowering drug atorvastatin (Lipitor), which is the hydroxymethylglutaryl CoA reductase inhibitor. Atorvastatin 121-133 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 158-193 24232833-1 2014 Ethyl (R)-4-cyano-3-hydroxybutanoate (HN) is an important chiral synthon for side chain of the cholesterol-lowering drug atorvastatin (Lipitor), which is the hydroxymethylglutaryl CoA reductase inhibitor. Atorvastatin 135-142 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 158-193 22989091-8 2012 Atorvastatin treatment of HepG2 cells resulted in increased HMGCR-1b mRNA levels, but unaltered proximal promoter activity compared to untreated cells. Atorvastatin 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 60-65 22989091-9 2012 In contrast, HMGCR-1c showed a more restricted transcription pattern, but was also induced by atorvastatin treatment. Atorvastatin 94-106 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 13-18 24233489-5 2014 Atorvastatin reduced HMGCoA-R enzymatic activity and intracellular cholesterol synthesis in vitro. Atorvastatin 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 21-29 24233489-7 2014 Atorvastatin at concentrations of 16 mumol/L inhibited HMGCoA-R activity by 50% in vascular smooth muscle cells, but the same concentration resulted in only 30% of HMGCoA-R activity in vascular smooth muscle cells in the presence of interleukin-1beta. Atorvastatin 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 55-63 24177008-2 2013 It has been suggested that the 3-hydroxy-3-methyl-glutarylcoenzyme-CoA (HMG-CoA) reductase inhibitor atorvastatin shows anticancer activity in prostate cancer cell lines. Atorvastatin 101-113 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 31-90 23471651-9 2013 Up-regulation of HMGCR following atorvastatin treatment was observed in 68 % of the paired samples with evaluable HMGCR expression (P = 0.0005). Atorvastatin 33-45 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 17-22 23471651-9 2013 Up-regulation of HMGCR following atorvastatin treatment was observed in 68 % of the paired samples with evaluable HMGCR expression (P = 0.0005). Atorvastatin 33-45 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 114-119 22108629-6 2012 CONCLUSION: This large prospective, randomised, open label trial will establish the effect of HMG-coA-reductase inhibitors (Atorvastatin) on cardiovascular risk in adult patients after successful coarctation repair. Atorvastatin 124-136 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 94-111 21427285-0 2012 Effect of HMGCR variant alleles on low-density lipoprotein cholesterol-lowering response to atorvastatin in healthy Korean subjects. Atorvastatin 92-104 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 10-15 21427285-1 2012 The investigators quantified the relationship between the genetic polymorphism of HMGCR (3-hydroxy-3-methylglutaryl coenzyme A reductase) and the low-density lipoprotein cholesterol (LDL-C)-lowering effects of atorvastatin in a prospective clinical study. Atorvastatin 210-222 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 82-87 21427285-8 2012 The HMGCR rs3846662 GG genotype was quantitatively documented to be a significant determinant for higher LDL-C level in basal state and possibly in response to atorvastatin. Atorvastatin 160-172 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 4-9 21871913-1 2011 Atorvastatin is a statin that inhibits the 3-hydroxy-methyl-glutaryl coenzyme A (HMG-CoA) reductase. Atorvastatin 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 43-99 22177940-6 2012 Our studies further concluded that Atorvastatin is most efficient inhibitor against both the isoforms of HMGCR whereas HMGCR isoform 2 shows less effectiveness with statins when compared with HMGCR isoform 1. Atorvastatin 35-47 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 105-110 23525139-7 2012 The search identified ten novel compounds, two of which have been demonstrated to interact with HMG-CoA reductase, the macromolecular target of atorvastatin. Atorvastatin 144-156 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 96-113